◀ Back to IL2

IL2 — NCAM1

Pathways - manually collected, often from reviews:

• OpenBEL Selventa BEL large corpus: NCAM1 → IL2 (increases)
  Evidence: In contrast, IL-2 induced the higher NK activity and increased CD16 and CD56 Ag expression.

Text-mined interactions from Literome

Donskov et al., Br J Cancer 2006 (Carcinoma, Renal Cell...) : In contrast, IL-2/HDC resulted in an unchanged number of circulating monocytes and intratumoral macrophages, and in addition, a significantly increased number of intratumoral CD56 ( + ) NK cells ( P=0.008 ) and CD8 ( + ) T cells ( P=0.019 ) compared with baseline
Yamamoto et al., Cell Immunol 1990 (Leukemia, Erythroblastic, Acute...) : Phenotypic analysis indicated that 1 U/ml IL2 plus K562 cell stimulation enhanced CD56+ and CD16+ cells
Doskali et al., J Immunother 2011 (Carcinoma, Hepatocellular...) : We recently showed that interleukin (IL)-2 stimulated CD56+ cells derived from the liver exert vigorous cytotoxicity against hepatocellular carcinoma ( HCC ) by their binding to the tumor necrosis factor related apoptosis inducing ligand expressed on natural killer cells and the corresponding death receptors, and exhibit inhibitory effects on hepatitis C virus ( HCV ) replication by production of a high level of interferon-?
Mulders et al., J Immunother 1998 (Carcinoma, Renal Cell...) : When compared with exogenous IL-2, RCC-Ad-IL-2 induced less growth expansion of TILs whereas a reduced CD56+ ( 23 +/- 14 % vs. 44 +/- 13 % ; p < 0.05 ) but increased CD3+CD4+ cell population ( 32 +/- 11 % vs. 15 +/- 6 % ; p < 0.05 ) with enhanced T cell-receptor use ( 59 +/- 10 % vs. 42 +/- 7 % ; p < 0.005 ) was determined
Baxevanis et al., Immunopharmacol Immunotoxicol 1998 : It is now well established that natural killer ( NK ) and lymphokine activated killer ( LAK ) cytotoxicity is mainly mediated by resting ( NK ) and IL-2 activated ( LAK ) CD56 positive ( + ) cells respectively
Fujimiya et al., Clin Cancer Res 1997 (Brain Neoplasms...) : In vitro interleukin 12 activation of peripheral blood CD3 ( + ) CD56 ( + ) and CD3 ( + ) CD56 ( - ) gammadelta T cells from glioblastoma patients